BioMed X teams with J&J on inflammation, drug delivery research. Stem cell firm Calidi inks licensing deals with U. of Chicago, City of Hope and Northwestern. MD Anderson teams with Blueprint and Hummingbird.

Goldman Sachs backs CRO Aragen, which it believes is well placed to gain from the “secular trend” of an outsourcing uptick by biopharma. Aragen has a string of alliances and is also assisting with both vaccine and test kit development against SARS-CoV-2 for its customers.

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Agilis Biotherapeutics has entered into a deal with synthetic biology firm Intrexon to develop DNA-based therapeutics for the rare genetic disease, Friedreich's ataxia.